Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px
Document › Details

BRAIN AG. (9/7/17). "Press Release: BRAIN AG Resolves Upon Capital Increase – New Long-term Investor Subscribes All New Shares [Ad-hoc News]". Zwingenberg.

Organisations Organisation BRAIN Biotechnology Reserarch and Information Network AG (FSE: BNN)
  Group BRAIN (Group)
  Organisation 2 DAH Beteiligungs GmbH
Products Product industrial biotechnology
  Product 2 finance
Persons Person Eck, Jürgen (BRAIN 201507– CEO before CTO + Co-founder)
  Person 2 Goebel, Frank (BRAIN 201703– CFO before Management Board Member for M&A Strategy before Royal Bank of Scotland)
     


The Management Board of the bioeconomy company BRAIN AG (ISIN DE0005203947 / WKN 520394), with approval of the Supervisory Board, has decided to increase the Company's share capital by approximately 10% against contributions in cash, partially using the Authorized Capital 2017/I. Shareholders' subscription rights have been excluded. The corresponding 1,641,434 registered no-par-value shares ("New Shares") were offered to a new long-term investor, by way of a private placement without prospectus. The New Shares were entirely subscribed by this investor and thus successfully placed. The investor is DAH Beteiligungs GmbH.

The gross proceeds for BRAIN AG from this transaction will amount to approximately EUR 28 million. Due to the capital increase, the company's share capital will increase from currently EUR 16,414,348.00 to EUR 18,055,782.00. The issue price was close to the BRAIN share price at the close of stock market trading of September 7, 2017, amounting to EUR 18.055.

After registration in the commercial register, the New Shares are to be admitted to trading, without a prospectus, on the regulated market of Frankfurt Stock Exchange expectedly on September 14, 2017, and to be included in the existing listing. The shares qualify for a dividend from October 1, 2016.

The proceeds from the capital increase shall be used, in particular, to finance small and medium sized acquisitions that are pursued by BRAIN AG in the course of its corporate growth strategy.


Information and Explanation of the Issuer to this News:

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this 'Toolbox of Nature' are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars - BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en.


Contact

B.R.A.I.N.
Biotechnology Research
And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany

Tel.: +49-6251-9331-16
Fax: +49-6251-9331-11
E-Mail: ir@brain-biotech.de
www.brain-biotech.de


Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

   
Record changed: 2017-09-17

Advertisement

Picture [LSF] Life-Sciences-France.com – The Business Web Portal 600x80px

More documents for BRAIN (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px